Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
The aim of this study is rate of acute graft-versus-host disease II-IV measured at day
 +365according to conventional criteria (Przepiorka et al. 1995) in patients with high risk
 non-Hodgkin lymphoma B subjects with Allogeneic Stem Cell Transplant
In addition to above:

 -  Rate of progression-free survival (PFS) at 12, 24, 36 and 60 months post-transplant
 defined as the time between the infusion of progenitors and the disease progression or
 death. Patients alive or in complete remission will be censored at the time of last
 follow up

 -  Transplant-related mortality (TRM) at 12, 24, 36 and 60 months after transplantation,
 defined as any death not caused directly by lymphoma (any death caused by complications
 related to transplantation).

 -  Overall survival (OS) defined as the time between infusion of progenitors and the
 patient's death from any cause. Alive Patients will be censored at the time of last
 follow-up

 -  Incidence of chronic graft versus host disease (GVHD) wide at 1 and 5 years according to
 conventional criteria (Atkinson et al. 1989) and Filipovich et al. (BBMT, 2005).

 -  Rate of event-free survival (DFS) defined as time interval between diagnosis of lymphoma
 and lymphoma progression or relapse or death if the above does not occur.

 -  Successful graft implantation: is defined as:

 1. º: three consecutive days with absolute neutrophil count greater than 0.5 * 109 / L

 2. ° thrombocythemia exceeds 20 * 109 / L.

 -  Reconstitution of the immune system: lymphocyte count populations CD20, CD3, CD4 and CD8
 and immunoglobulinemia serum (days +100, 180, 360, 18 months and 24 months).

 -  intercurrent infections. All sorts of infections (viral, fungal and bacterial)will be
 recorded

 -  Safety assessment by the standards of Common Terminology Criteria for adverse events v.
 4.0
Inclusion Criteria:

 1. Subjects who have given their informed consent before any study-specific procedures

 2. Histopathological diagnostic of NHL cell B CD 20 + B of different histologic subtypes:

 3. High risk CD +20 Lymphoma having at least one of the following characteristics:

 -  Less than a partial remission after two courses of treatment

 -  Relapse after autologous peripheral blood stem cell (PBSCT)

 -  Evidence of measurable disease (With CT and PET or PET / CT) three months after
 PBSCT

 -  Hematopoietic precursors improper count in patients with relapsed or partial
 remission after two treatment lines that prevent the realization of a PBSCT.

 -  Patients after first relapse in RP after two lines of treatment in whom the
 probability of freedom from progression per year is very low due to risk factors
 such as: first CR less than 12 months after PBSCT low SLP, etc..

 4. Age between 18 and 65 years

 5. ECOG between 0 to 1 (Appendix III).

 6. Subjects who are HBgAG negative, anti-HBc positive and HBV DNA negative may be include
 in the study but must undergo HBV DNA monitoring

 7. Adequate lung Function

 8. Cardiac ejection greater than 40% as measured by scintigraphy or echocardiography.

 9. Adequate renal and hepatic function defined by the following biochemical parameters

 10. The disease status prior to transplantation had to be in place in accordance with the
 criteria of Revised Response Criteria for Malignant Lymphoma, Cheson 2007. CT and PET
 or PET / CT.

 11. Availability of a histocompatible donor (9 to 10/10 loci) family or unrelated

 12. Adults with ability to procreate must commit to use an effective method of birth
 control during the study treatment and at least 6 months.

 Exclusion Criteria:

 1. Refractory disease at the time of transplantation

 2. Progressive disease at the time of transplantation.

 3. ECOG≤2

 4. Lymphoma associated with infection with human immunodeficiency virus (HIV).

 5. Test positive for HIV.

 6. Presence of anti-murine antibodies (HAMA) or (HACA).

 7. Treatment with any marketed or experimental drug administered not in a period between
 5 terminal half-lives of clearance of therapy or 4 weeks before enrollment

 8. Participation in another interventional clinical trial.

 9. Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months
 prior to start of therapy. This is generally required and may be excluded as
 applicable.

 10. Hepatitis B positive serology

 11. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg.

 12. Positive serology for hepatitis C (HC) defined as a positive test for HCAb.

 13. Active liver or biliary disease (with exception of Gilbert's disease, cholelithiasis,
 metastases).

 14. Other past or current malignancy.

 15. Chronic infectious disease that requires ongoing treatment with systemic antibiotics,
 antifungal or antiviral drugs

 16. History of cerebrovascular disease active in the last 6 months or event with
 significant symptoms or sequelae.

 17. Clinically significant heart disease, such as unstable angina, acute myocardial
 infarction in the six months prior to inclusion, congestive heart failure (grades
 III-IV NYHA) and arrhythmia unless it is controlled by treatment, except for premature
 or disorders Mild driving.

 18. Concurrent medical disorder, uncontrolled and important, such as kidney disease,
 liver, digestive, endocrine, pulmonary, neurological, brain, psychiatric, or which in
 the opinion of the investigator may represent a risk to the patient

 19. Pregnancy or breastfeeding

 20. Women of childbearing potential, including those whose last menstrual period was one
 year prior to screening.

 21. Men unable or unwilling to use contraception

 22. Patients with hypersensitivity to fludarabine, melphalan, thiotepa, tacrolimus,
 sirolimus and / or any excipients.